导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -11.73% | 3860/4773 |
| 近一周 | -2.13% | 3437/5465 |
| 近一月 | -1.80% | 1306/5421 |
| 近一季 | -0.57% | 1092/5231 |
| 近半年 | -8.82% | 3562/4920 |
| 近一年 | -16.80% | 3843/4394 |
| 近两年 | 30.70% | 2248/2954 |
| 近三年 | 29.37% | 1110/2253 |
| 成立以来 | -2.87% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-8.31% 4275/4961 |
-11.27% 4262/5312 |
- - |
- - |
| 2025 | 22.20% 1990/4813 |
17.04% 136/3635 |
1.65% 2244/4076 |
11.03% 3206/4524 |
-7.49% 3802/4813 |
| 2024 | 36.05% 50/3463 |
1.87% 850/2808 |
13.66% 16/3014 |
17.70% 1139/3129 |
-0.17% 1335/3463 |
| 2023 | -14.85% 1625/2656 |
-0.64% 1812/2280 |
-1.66% 513/2385 |
-6.61% 1487/2515 |
-6.69% 1876/2655 |
| 2022 | -8.53% 156/2207 |
-11.25% 493/1919 |
8.95% 314/2016 |
-16.01% 1388/2113 |
12.64% 126/2208 |
| 2021 | -19.49% 1173/1822 |
3.40% 178/1255 |
-2.32% 1199/1330 |
-14.46% 1371/1466 |
-6.81% 1553/1822 |
| 2020 | -6.93% 981/1250 |
-12.44% 156/280 |
3.04% 263/295 |
-6.48% 1123/1164 |
10.31% 601/1184 |
| 2019 | 14.76% 696/1092 |
9.74% 129/258 |
-0.47% 191/268 |
-3.12% 200/253 |
8.44% 95/266 |
| 2018 | - - |
- - |
- - |
- - |
-8.67% 103/241 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.6144 | 32.25% |
| 景顺长城中证港股通创新药ETF | 1.6764 | 32.17% |
| 港股医疗 | 0.9539 | 31.90% |
| 港股医疗ETF | 1.4546 | 31.90% |
| 港股通医疗ETF工银 | 0.9639 | 31.81% |
| 港股通医疗ETF华宝 | 0.9752 | 31.64% |
| 万家中证港股通创新药ETF发起式联接A | 1.4069 | 31.06% |
| 万家中证港股通创新药ETF发起式联接C | 1.4061 | 30.98% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 嘉实中证港股通创新药指数发起式A | 0.8590 | 30.57% |
| 南方恒生中国企业ETF VS. 长安沪深300非周期A(740101) |